# –°—Ç–∞–¥–∏—è 3 ‚Äî –ì–µ–Ω–µ—Ä–∞—Ü–∏—è —Å–∏–Ω–æ–ø—Å–∏—Å–∞ –ø—Ä–æ—Ç–æ–∫–æ–ª–∞ (–∞—Ä—Ö–∏—Ç–µ–∫—Ç—É—Ä–∞ v3)

## –û–±–∑–æ—Ä

–°—Ç–∞–¥–∏—è 3 –ø—Ä–∏–Ω–∏–º–∞–µ—Ç —Ä–µ–∑—É–ª—å—Ç–∞—Ç—ã Stage 1 (–æ—Ä–∏–≥–∏–Ω–∞–ª—å–Ω—ã–π –ø—Ä–µ–ø–∞—Ä–∞—Ç –∏–∑ —Ä–µ–µ—Å—Ç—Ä–∞ –ï–ê–≠–°) –∏ Stage 2 (–§–ö –ø–∞—Ä–∞–º–µ—Ç—Ä—ã –∏–∑ 7+ –±–∞–∑ –¥–∞–Ω–Ω—ã—Ö) –∏ –≥–µ–Ω–µ—Ä–∏—Ä—É–µ—Ç –ø–æ–ª–Ω—ã–π —Å–∏–Ω–æ–ø—Å–∏—Å –ø—Ä–æ—Ç–æ–∫–æ–ª–∞ –∏—Å—Å–ª–µ–¥–æ–≤–∞–Ω–∏—è –±–∏–æ—ç–∫–≤–∏–≤–∞–ª–µ–Ω—Ç–Ω–æ—Å—Ç–∏ –≤ —Ñ–æ—Ä–º–∞—Ç–µ Word (.docx).

**–ö–ª—é—á–µ–≤–æ–π –ø—Ä–∏–Ω—Ü–∏–ø:** –º–∞–∫—Å–∏–º—É–º –ø—Ä–æ–≥—Ä–∞–º–º–Ω—ã—Ö —à–∞–±–ª–æ–Ω–æ–≤ (–±—ã—Å—Ç—Ä–æ, –¥–µ—Ç–µ—Ä–º–∏–Ω–∏—Ä–æ–≤–∞–Ω–Ω–æ), –º–∏–Ω–∏–º—É–º LLM-–≤—ã–∑–æ–≤–æ–≤ (—Ç–æ–ª—å–∫–æ —Ç–∞–º, –≥–¥–µ –Ω—É–∂–µ–Ω –∞–Ω–∞–ª–∏–∑ –¥–∞–Ω–Ω—ã—Ö –∫–æ–Ω–∫—Ä–µ—Ç–Ω–æ–≥–æ –ø—Ä–µ–ø–∞—Ä–∞—Ç–∞).

- **~20 –ø–æ–ª–µ–π** –≥–µ–Ω–µ—Ä–∏—Ä—É—é—Ç—Å—è **–ø—Ä–æ–≥—Ä–∞–º–º–Ω–æ** (—à–∞–±–ª–æ–Ω—ã –∏–∑ instructions.docx + —Ñ–æ—Ä–º—É–ª—ã)
- **3 LLM-–≤—ã–∑–æ–≤–∞** (–≤–º–µ—Å—Ç–æ 6 –≤ v1) ‚Äî –¥–∏–∑–∞–π–Ω+–∑–∞–¥–∞—á–∏, –∫—Ä–∏—Ç–µ—Ä–∏–∏, –æ–ø–∏—Å–∞–Ω–∏—è –ø—Ä–µ–ø–∞—Ä–∞—Ç–æ–≤

---

## –ü–æ—Ç–æ–∫–∏ –¥–∞–Ω–Ω—ã—Ö

```
                ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
                ‚îÇ         –ü–æ–ª—å–∑–æ–≤–∞—Ç–µ–ª—å—Å–∫–∏–π –≤–≤–æ–¥    ‚îÇ
                ‚îÇ  test_drug_name, dosage_form,    ‚îÇ
                ‚îÇ  strength, fasting_fed, gender,  ‚îÇ
                ‚îÇ  cv_intra_user, design_preference‚îÇ
                ‚îÇ  use_rsabe, study_phases, ...    ‚îÇ
                ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                                ‚îÇ
         ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îº‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
         ‚îÇ                      ‚îÇ                        ‚îÇ
         ‚ñº                      ‚ñº                        ‚ñº
  ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê   ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê   ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
  ‚îÇ   Stage 1    ‚îÇ   ‚îÇ     Stage 2      ‚îÇ   ‚îÇ   Rule 85 (.md)   ‚îÇ
  ‚îÇ  DrugInfo    ‚îÇ   ‚îÇ  Stage2Result    ‚îÇ   ‚îÇ  –ù–æ—Ä–º–∞—Ç–∏–≤–Ω–∞—è –±–∞–∑–∞ ‚îÇ
  ‚îÇ  (—Ä–µ–µ—Å—Ç—Ä)    ‚îÇ   ‚îÇ  (–§–ö –ø–∞—Ä–∞–º–µ—Ç—Ä—ã)  ‚îÇ   ‚îÇ                   ‚îÇ
  ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò   ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò   ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
         ‚îÇ                    ‚îÇ                        ‚îÇ
         ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò                        ‚îÇ
                      ‚ñº                                ‚îÇ
              ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê                        ‚îÇ
              ‚îÇ Stage3Input   ‚îÇ                        ‚îÇ
              ‚îÇ (–≤—Å–µ –≤—Ö–æ–¥—ã)   ‚îÇ                        ‚îÇ
              ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò                        ‚îÇ
                      ‚îÇ                                ‚îÇ
                      ‚ñº                                ‚îÇ
              ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê                        ‚îÇ
              ‚îÇcompute_derived‚îÇ                        ‚îÇ
              ‚îÇ  (—Ä–∞—Å—á—ë—Ç—ã)    ‚îÇ                        ‚îÇ
              ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò                        ‚îÇ
                      ‚îÇ                                ‚îÇ
           ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îº‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê                     ‚îÇ
           ‚ñº                     ‚ñº                     ‚ñº
  ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê   ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê   ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
  ‚îÇ  –ü–†–û–ì–†–ê–ú–ú–ù–´–ï   ‚îÇ   ‚îÇ  3 LLM-–í–´–ó–û–í–ê ‚îÇ   ‚îÇ collect_all_data ‚îÇ
  ‚îÇ  –®–ê–ë–õ–û–ù–´       ‚îÇ   ‚îÇ               ‚îÇ   ‚îÇ  (–¥–∞–Ω–Ω—ã–µ –∏–∑ S2)  ‚îÇ
  ‚îÇ  (~20 –ø–æ–ª–µ–π)   ‚îÇ   ‚îÇ  criteria +   ‚îÇ   ‚îÇ                  ‚îÇ
  ‚îÇ                ‚îÇ   ‚îÇ  drug_safety   ‚îÇ   ‚îÇ                  ‚îÇ
  ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò   ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò   ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
          ‚îÇ                    ‚îÇ
          ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                   ‚ñº
           ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
           ‚îÇ   –°–ò–ù–û–ü–°–ò–°    ‚îÇ
           ‚îÇ  (dict –ø–æ–ª–µ–π) ‚îÇ
           ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                   ‚ñº
           ‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
           ‚îÇ generate_docx ‚îÇ
           ‚îÇ  (Word .docx) ‚îÇ
           ‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
```

---

## –í—Ö–æ–¥–Ω—ã–µ –ø–∞—Ä–∞–º–µ—Ç—Ä—ã (Stage3Input)

| –ü–∞—Ä–∞–º–µ—Ç—Ä | –¢–∏–ø | –û–ø–∏—Å–∞–Ω–∏–µ | –ü–æ —É–º–æ–ª—á–∞–Ω–∏—é |
|---|---|---|---|
| `drug_info` | DrugInfo | –û—Ä–∏–≥–∏–Ω–∞–ª—å–Ω—ã–π –ø—Ä–µ–ø–∞—Ä–∞—Ç –∏–∑ Stage 1 | ‚Äî |
| `s2` | Stage2Result | –í—Å–µ –¥–∞–Ω–Ω—ã–µ Stage 2 (–§–ö, –û–•–õ–ü, –í–∏–¥–∞–ª—å, FDA PSG...) | ‚Äî |
| `test_drug_name` | str | –ù–∞–∑–≤–∞–Ω–∏–µ –≥–µ–Ω–µ—Ä–∏–∫–∞ (–≤–≤–æ–¥–∏—Ç –ø–æ–ª—å–∑–æ–≤–∞—Ç–µ–ª—å) | "" |
| `dosage_form` | str | –õ–µ–∫–∞—Ä—Å—Ç–≤–µ–Ω–Ω–∞—è —Ñ–æ—Ä–º–∞ | "" |
| `strength` | str | –î–æ–∑–∏—Ä–æ–≤–∫–∞ (–Ω–∞–ø—Ä. "400 –º–≥") | "" |
| `sponsor` | str | –°–ø–æ–Ω—Å–æ—Ä | "–•–•–•–•–•, –†–æ—Å—Å–∏—è" |
| `fasting_fed` | str | –†–µ–∂–∏–º: "fasting" / "fed" / "both" / "" (–∞–≤—Ç–æ) | "" |
| `cv_intra_user` | float | CVintra –æ—Ç –ø–æ–ª—å–∑–æ–≤–∞—Ç–µ–ª—è (0 = –∏–∑ Stage 2) | 0.0 |
| `use_rsabe` | bool | –ü—Ä–∏–Ω—É–¥–∏—Ç–µ–ª—å–Ω–æ RSABE –¥–ª—è Cmax | False |
| `design_preference` | str | –î–∏–∑–∞–π–Ω: "2x2" / "replicated" / "parallel" / "" | "" |
| `study_phases` | str | "single" / "multiple" | "single" |
| `gender` | str | "both" / "male" / "female" | "both" |
| `age_range` | str | –í–æ–∑—Ä–∞—Å—Ç–Ω–æ–π –¥–∏–∞–ø–∞–∑–æ–Ω | "18-45" |
| `additional_requirements` | str | –°–≤–æ–±–æ–¥–Ω—ã–π —Ç–µ–∫—Å—Ç —Å –¥–æ–ø. —Ç—Ä–µ–±–æ–≤–∞–Ω–∏—è–º–∏ | "" |

---

## –í—ã—á–∏—Å–ª—è–µ–º—ã–µ –∑–Ω–∞—á–µ–Ω–∏—è (compute_derived)

–ù–∞ –æ—Å–Ω–æ–≤–µ –≤—Ö–æ–¥–Ω—ã—Ö –¥–∞–Ω–Ω—ã—Ö –≤—ã—á–∏—Å–ª—è—é—Ç—Å—è:

| –ó–Ω–∞—á–µ–Ω–∏–µ | –§–æ—Ä–º—É–ª–∞ / –ª–æ–≥–∏–∫–∞ |
|---|---|
| **cv_intra** | `cv_intra_user` > 0 ‚Üí user; –∏–Ω–∞—á–µ ‚Üí Stage2 PK ‚Üí FDA PSG threshold |
| **washout_days** | ‚åà5 √ó T¬Ω / 24‚åâ –¥–Ω–µ–π |
| **vomit_criterion_h** | 2 √ó Tmax —á–∞—Å–æ–≤ |
| **design** | –ò–∑ preference ‚Üí –∏–∑ CVintra/HVD/NTI ‚Üí default 2x2 |
| **sample_size** | PowerTOST (scipy nct / normal approx) |
| **n_to_screen** | ‚åàn_total / 0.80‚åâ (20% —Å–∫—Ä–∏–Ω-—Ñ–µ–π–ª) |
| **timepoints** | –ê–ª–≥–æ—Ä–∏—Ç–º –∏–∑ timepoints.py (Tmax + T¬Ω ‚Üí –æ–ø—Ç–∏–º–∞–ª—å–Ω—ã–π –≥—Ä–∞—Ñ–∏–∫) |
| **fasting_text** | –ò–∑ user preference ‚Üí –∏–∑ FDA PSG ‚Üí default "–Ω–∞—Ç–æ—â–∞–∫" |
| **RSABE limits** | –ü—Ä–∏ CVintra > 30% + replicated: exp(¬±k¬∑swR), k=0.760 |
| **study_duration_days** | 14 + n_periods √ó pk_days + n_washouts √ó washout + 7 |

---

## –ü—Ä–æ–≥—Ä–∞–º–º–Ω—ã–µ –ø–æ–ª—è (20+ –ø–æ–ª–µ–π)

–ì–µ–Ω–µ—Ä–∏—Ä—É—é—Ç—Å—è —Ñ—É–Ω–∫—Ü–∏–µ–π `generate_programmatic_fields()` –±–µ–∑ –≤—ã–∑–æ–≤–∞ LLM:

| # | –ü–æ–ª–µ | –ú–µ—Ç–æ–¥ | –ò—Å—Ç–æ—á–Ω–∏–∫ |
|---|---|---|---|
| 1 | protocol_title | –®–∞–±–ª–æ–Ω | –í—Å–µ –≤—ã—á–∏—Å–ª–µ–Ω–Ω—ã–µ –∑–Ω–∞—á–µ–Ω–∏—è |
| 2 | protocol_id | `{–ú–ù–ù}-BE` | Stage 1 |
| 3 | sponsor | –í–≤–æ–¥ –ø–æ–ª—å–∑–æ–≤–∞—Ç–µ–ª—è | User / default |
| 4 | phase | –ö–æ–Ω—Å—Ç–∞–Ω—Ç–∞ | "–ò—Å—Å–ª–µ–¥–æ–≤–∞–Ω–∏–µ –±–∏–æ—ç–∫–≤–∏–≤–∞–ª–µ–Ω—Ç–Ω–æ—Å—Ç–∏" |
| 5 | study_objectives | –®–∞–±–ª–æ–Ω | test_drug, ref_drug, fasting |
| 6 | tasks | –®–∞–±–ª–æ–Ω | INN, dose_type |
| 7 | study_design | –®–∞–±–ª–æ–Ω + rationale | Design, T¬Ω, washout |
| 8 | methodology | –°–ª–æ–∂–Ω—ã–π —à–∞–±–ª–æ–Ω | –í—Å–µ computed: periods, groups, sampling |
| 9 | sample_size_text | –®–∞–±–ª–æ–Ω + —Ñ–æ—Ä–º—É–ª–∞ | CV, PowerTOST, dropout, screen fail |
| 10 | study_periods | –®–∞–±–ª–æ–Ω —Å –¥–∞—Ç–∞–º–∏ | Visit schedule, days |
| 11 | study_duration | –®–∞–±–ª–æ–Ω | study_duration_days |
| 12 | pk_parameters | –®–∞–±–ª–æ–Ω | INN |
| 13 | analytical_method | –®–∞–±–ª–æ–Ω | INN |
| 14 | be_criteria | –®–∞–±–ª–æ–Ω + RSABE | CV, k, swR (–µ—Å–ª–∏ RSABE) |
| 15 | sample_size_calculation | –§–æ—Ä–º—É–ª–∞ + –ø–æ—è—Å–Ω–µ–Ω–∏—è | CV, œÉ¬≤_w, Œ¥, N |
| 16 | statistical_methods | –®–∞–±–ª–æ–Ω + RSABE | INN, ANOVA model |
| 17 | blinding_randomization | –®–∞–±–ª–æ–Ω | Groups, sequences |
| 18 | ethical_aspects | –ö–æ–Ω—Å—Ç–∞–Ω—Ç–∞ | Sponsor |
| 19 | protocol_version | `1.0 –æ—Ç {–¥–∞—Ç–∞}` | today() |

---

## LLM-–≤—ã–∑–æ–≤—ã (3 —à—Ç—É–∫–∏)

### CALL 1: `study_design_analysis`
**–ü–æ–ª—è:** tasks, study_design

**–í—Ö–æ–¥–Ω—ã–µ –¥–∞–Ω–Ω—ã–µ:**
- –û–•–õ–ü: —Å–ø–æ—Å–æ–± –ø—Ä–∏–º–µ–Ω–µ–Ω–∏—è –∏ –¥–æ–∑—ã (dosing_text), —Ñ–∞—Ä–º–∞–∫–æ–∫–∏–Ω–µ—Ç–∏–∫–∞ (pk_text), –ª–µ–∫–∞—Ä—Å—Ç–≤–µ–Ω–Ω–∞—è —Ñ–æ—Ä–º–∞ (form_text)
- –í–∏–¥–∞–ª—å: –¥–∞–Ω–Ω—ã–µ –æ –ø—Ä–µ–ø–∞—Ä–∞—Ç–µ, –§–ö –≤–µ—â–µ—Å—Ç–≤–∞
- FDA PSG: –¥–∏–∑–∞–π–Ω (fasting/fed), –∫–æ–º–º–µ–Ω—Ç–∞—Ä–∏–∏, –¥–æ–∑–∏—Ä–æ–≤–∫–∞
- Computed: design_details, t_half, cv_intra, washout_days
- Rule 85: –ø. 15‚Äì16 (–î–∏–∑–∞–π–Ω)

**–ó–∞—á–µ–º LLM:**
- –û–ø—Ä–µ–¥–µ–ª–∏—Ç—å –∫—Ä–∞—Ç–Ω–æ—Å—Ç—å –¥–æ–∑–∏—Ä–æ–≤–∞–Ω–∏—è (–æ–¥–Ω–æ–∫—Ä–∞—Ç–Ω–æ–µ/–º–Ω–æ–≥–æ–∫—Ä–∞—Ç–Ω–æ–µ) –ø–æ –¥–∞–Ω–Ω—ã–º –û–•–õ–ü:
  - –ú–Ω–æ–≥–æ–∫—Ä–∞—Ç–Ω–æ–µ –Ω—É–∂–Ω–æ –¢–û–õ–¨–ö–û –ø—Ä–∏: –Ω–µ–ø–µ—Ä–µ–Ω–æ—Å–∏–º–æ—Å—Ç–∏ –æ–¥–Ω–æ–∫—Ä–∞—Ç–Ω–æ–π –¥–æ–∑—ã, –Ω–µ–≤–æ–∑–º–æ–∂–Ω–æ—Å—Ç–∏ –∑–∞—Ñ–∏–∫—Å–∏—Ä–æ–≤–∞—Ç—å –∫–æ–Ω—Ü–µ–Ω—Ç—Ä–∞—Ü–∏—é, –º–æ–¥–∏—Ñ–∏—Ü–∏—Ä–æ–≤–∞–Ω–Ω–æ–º –≤—ã—Å–≤–æ–±–æ–∂–¥–µ–Ω–∏–∏
- –û–±–æ—Å–Ω–æ–≤–∞—Ç—å –≤—ã–±—Ä–∞–Ω–Ω—ã–π –¥–∏–∑–∞–π–Ω –∏—Å—Å–ª–µ–¥–æ–≤–∞–Ω–∏—è —Å —É—á—ë—Ç–æ–º —Å–ø–µ—Ü–∏—Ñ–∏–∫–∏ –ø—Ä–µ–ø–∞—Ä–∞—Ç–∞
- –î–æ–ø–æ–ª–Ω–∏—Ç—å –ø—Ä–æ–≥—Ä–∞–º–º–Ω—ã–π —Ç–µ–∫—Å—Ç –∫–ª–∏–Ω–∏—á–µ—Å–∫–æ–π –∞—Ä–≥—É–º–µ–Ω—Ç–∞—Ü–∏–µ–π

**–ú–µ—Ö–∞–Ω–∏–∑–º:** LLM –ø–æ–ª—É—á–∞–µ—Ç –ø—Ä–æ–≥—Ä–∞–º–º–Ω–æ —Å–≥–µ–Ω–µ—Ä–∏—Ä–æ–≤–∞–Ω–Ω—ã–µ —Ç–µ–∫—Å—Ç—ã –∑–∞–¥–∞—á –∏ –¥–∏–∑–∞–π–Ω–∞ –∫–∞–∫ ¬´–±–∞–∑—É¬ª, –∏ —É–ª—É—á—à–∞–µ—Ç/–¥–æ–ø–æ–ª–Ω—è–µ—Ç –∏—Ö –Ω–∞ –æ—Å–Ω–æ–≤–µ –¥–∞–Ω–Ω—ã—Ö –û–•–õ–ü –∏ FDA PSG.

### CALL 2: `criteria`
**–ü–æ–ª—è:** inclusion_criteria, exclusion_criteria, withdrawal_criteria

**–í—Ö–æ–¥–Ω—ã–µ –¥–∞–Ω–Ω—ã–µ:**
- –û–•–õ–ü: –ø—Ä–æ—Ç–∏–≤–æ–ø–æ–∫–∞–∑–∞–Ω–∏—è, –æ—Å–æ–±—ã–µ —É–∫–∞–∑–∞–Ω–∏—è, –±–µ—Ä–µ–º–µ–Ω–Ω–æ—Å—Ç—å, –≤–∑–∞–∏–º–æ–¥–µ–π—Å—Ç–≤–∏—è, –ù–Ø, –ø–æ–∫–∞–∑–∞–Ω–∏—è
- –í–∏–¥–∞–ª—å: –ø—Ä–æ—Ç–∏–≤–æ–ø–æ–∫–∞–∑–∞–Ω–∏—è –≤–µ—â–µ—Å—Ç–≤–∞, –ø–æ–∫–∞–∑–∞–Ω–∏—è
- Computed: gender, age_range, vomit_criterion_h
- Rule 85: –ø. 26‚Äì31 (–°—É–±—ä–µ–∫—Ç—ã)

**–ó–∞—á–µ–º LLM:**
- –ù—É–∂–Ω–æ –∞–¥–∞–ø—Ç–∏—Ä–æ–≤–∞—Ç—å —à–∞–±–ª–æ–Ω–Ω—ã–µ –∫—Ä–∏—Ç–µ—Ä–∏–∏ –∫ –∫–æ–Ω–∫—Ä–µ—Ç–Ω–æ–º—É –ø—Ä–µ–ø–∞—Ä–∞—Ç—É
- –£–±—Ä–∞—Ç—å/–¥–æ–±–∞–≤–∏—Ç—å –ø–æ–ª –≤ –∑–∞–≤–∏—Å–∏–º–æ—Å—Ç–∏ –æ—Ç –ø–æ–∫–∞–∑–∞–Ω–∏–π
- –î–æ–±–∞–≤–∏—Ç—å —Å–ø–µ—Ü–∏—Ñ–∏—á–µ—Å–∫–∏–µ –ø—Ä–æ—Ç–∏–≤–æ–ø–æ–∫–∞–∑–∞–Ω–∏—è –∏–∑ –û–•–õ–ü
- –†–∞—Å—Å—á–∏—Ç–∞—Ç—å –∫—Ä–∏—Ç–µ—Ä–∏–π —Ä–≤–æ—Ç—ã

### CALL 3: `drug_safety`
**–ü–æ–ª—è:** test_drug_details, reference_drug_details, safety_analysis

**–í—Ö–æ–¥–Ω—ã–µ –¥–∞–Ω–Ω—ã–µ:**
- –û–•–õ–ü: —Å–æ—Å—Ç–∞–≤, —Ñ–æ—Ä–º–∞, –≤—Å–ø–æ–º–æ–≥–∞—Ç–µ–ª—å–Ω—ã–µ –≤–µ—â–µ—Å—Ç–≤–∞, —Ö—Ä–∞–Ω–µ–Ω–∏–µ, —Å—Ä–æ–∫ –≥–æ–¥–Ω–æ—Å—Ç–∏, –ù–Ø, –ø–µ—Ä–µ–¥–æ–∑–∏—Ä–æ–≤–∫–∞
- –í–∏–¥–∞–ª—å: –¥–∞–Ω–Ω—ã–µ –æ –ø—Ä–µ–ø–∞—Ä–∞—Ç–µ (–§–ö, —Å–æ—Å—Ç–∞–≤)
- DrugBank: –º–µ—Ç–∞–±–æ–ª–∏–∑–º, —ç–ª–∏–º–∏–Ω–∞—Ü–∏—è
- FDA PSG: –¥–æ–∑–∏—Ä–æ–≤–∫–∞

**–ó–∞—á–µ–º LLM:**
- –ù—É–∂–Ω–æ —Å–∏–Ω—Ç–µ–∑–∏—Ä–æ–≤–∞—Ç—å –¥–∞–Ω–Ω—ã–µ –∏–∑ –Ω–µ—Å–∫–æ–ª—å–∫–∏—Ö –∏—Å—Ç–æ—á–Ω–∏–∫–æ–≤
- –ó–∞–ø–æ–ª–Ω–∏—Ç—å —Å—Ç—Ä—É–∫—Ç—É—Ä–∏—Ä–æ–≤–∞–Ω–Ω—É—é –∫–∞—Ä—Ç–æ—á–∫—É –ø—Ä–µ–ø–∞—Ä–∞—Ç–∞
- –û–ø—Ä–µ–¥–µ–ª–∏—Ç—å —Å–ø–µ—Ü–∏—Ñ–∏—á–µ—Å–∫–∏–µ –∞–Ω–∞–ª–∏–∑—ã –±–µ–∑–æ–ø–∞—Å–Ω–æ—Å—Ç–∏

---

## RSABE (Reference-Scaled Average Bioequivalence)

–ü—Ä–∏–º–µ–Ω—è–µ—Ç—Å—è –∫–æ–≥–¥–∞:
1. –î–∏–∑–∞–π–Ω replicated (3- –∏–ª–∏ 4-way)
2. CVwR (within-subject CV —Ä–µ—Ñ–µ—Ä–µ–Ω—Ç–∞) > 30%
3. –ò–ª–∏ —è–≤–Ω–æ –∑–∞–ø—Ä–æ—à–µ–Ω–æ –ø–æ–ª—å–∑–æ–≤–∞—Ç–µ–ª–µ–º

–§–æ—Ä–º—É–ª—ã:
```
swR = ‚àö(ln(1 + CV¬≤))     –≥–¥–µ CV = CVintra/100
k = 0.760
–ì—Ä–∞–Ω–∏—Ü—ã Cmax: [exp(-k¬∑swR) √ó 100% ; exp(k¬∑swR) √ó 100%]
```

–ü—Ä–∏ CV = 30%: –≥—Ä–∞–Ω–∏—Ü—ã = 80.00‚Äì125.02% (‚âà —Å—Ç–∞–Ω–¥–∞—Ä—Ç–Ω—ã–µ)
–ü—Ä–∏ CV = 45%: –≥—Ä–∞–Ω–∏—Ü—ã = 72.15‚Äì138.59%

AUC –≤—Å–µ–≥–¥–∞ –æ—Ü–µ–Ω–∏–≤–∞–µ—Ç—Å—è –ø–æ —Å—Ç–∞–Ω–¥–∞—Ä—Ç–Ω—ã–º –≥—Ä–∞–Ω–∏—Ü–∞–º 80‚Äì125%.

---

## –†–∞—Å—á—ë—Ç –≤—ã–±–æ—Ä–∫–∏

```
œÉ¬≤_w = ln(1 + CV¬≤)
Œ¥ = ln(Œ∏)                   Œ∏ = 1.25 (—Å—Ç–∞–Ω–¥–∞—Ä—Ç) –∏–ª–∏ 1.1111 (NTI)
N_eval = 2¬∑(Z_Œ± + Z_Œ≤)¬≤¬∑œÉ¬≤_w / Œ¥¬≤    (normal approx)

N_total = ‚åàN_eval / (1 - 0.15)‚åâ       (dropout 15%)
N_screen = ‚åàN_total / (1 - 0.20)‚åâ     (screen fail 20%)
```

–ú–∏–Ω–∏–º—É–º: 12 –¥–æ–±—Ä–æ–≤–æ–ª—å—Ü–µ–≤ (–ü—Ä–∞–≤–∏–ª–æ 85, –ø. 26).

---

## –ü—Ä–∏–º–µ—Ä: –ê–º–ª–æ–¥–∏–ø–∏–Ω 10 –º–≥

### –í—Ö–æ–¥–Ω—ã–µ –¥–∞–Ω–Ω—ã–µ
```
–ú–ù–ù: –∞–º–ª–æ–¥–∏–ø–∏–Ω
–û—Ä–∏–≥–∏–Ω–∞–ª—å–Ω—ã–π –ø—Ä–µ–ø–∞—Ä–∞—Ç: –ù–æ—Ä–≤–∞—Å–∫¬Æ (Viatris Specialty LLC)
–ò—Å—Å–ª–µ–¥—É–µ–º—ã–π: –ê–º–ª–æ–¥–∏–ø–∏–Ω-–¢–µ—Å—Ç, —Ç–∞–±–ª–µ—Ç–∫–∏, 10 –º–≥
–°–ø–æ–Ω—Å–æ—Ä: –û–û–û "–§–∞—Ä–º–∞–¢–µ—Å—Ç", –†–æ—Å—Å–∏—è

–§–ö –ø–∞—Ä–∞–º–µ—Ç—Ä—ã (–∏–∑ Stage 2):
  Cmax = 6.0 –Ω–≥/–º–ª (e-Drug3D)
  AUC = 200.0 –Ω–≥*—á/–º–ª (e-Drug3D)
  Tmax = 6.0 —á (–í–∏–¥–∞–ª—å)
  T¬Ω = 35.0 —á (DrugBank)
  CVintra = 25.0% (CVintra/PMC)

–ü–∞—Ä–∞–º–µ—Ç—Ä—ã Stage 3:
  –†–µ–∂–∏–º: –Ω–∞—Ç–æ—â–∞–∫
  –ü–æ–ª: –º—É–∂—á–∏–Ω—ã –∏ –∂–µ–Ω—â–∏–Ω—ã
  –í–æ–∑—Ä–∞—Å—Ç: 18-45 –ª–µ—Ç
  –î–æ–∑–∞: –æ–¥–Ω–æ–∫—Ä–∞—Ç–Ω–∞—è
```

### –í—ã—á–∏—Å–ª–µ–Ω–Ω—ã–µ –∑–Ω–∞—á–µ–Ω–∏—è
```
–î–∏–∑–∞–π–Ω: 2x2 (CVintra < 30%)
–û—Ç–º—ã–≤–æ—á–Ω—ã–π: ‚åà5 √ó 35 / 24‚åâ = 8 –¥–Ω–µ–π
–ö—Ä–∏—Ç–µ—Ä–∏–π —Ä–≤–æ—Ç—ã: 2 √ó 6.0 = 12.0 —á
–í—ã–±–æ—Ä–∫–∞: 20 –¥–æ–±. (10 –Ω–∞ –≥—Ä.), —Å–∫—Ä–∏–Ω–∏—Ä–æ–≤–∞—Ç—å –¥–æ 26
–ü—Ä–æ–¥–æ–ª–∂–∏—Ç–µ–ª—å–Ω–æ—Å—Ç—å: ~39 –¥–Ω–µ–π
–ì—Ä–∞—Ñ–∏–∫ –∫—Ä–æ–≤–∏: 0 (–¥–æ –ø—Ä–∏—ë–º–∞), 30 –º–∏–Ω, 45 –º–∏–Ω, 1 —á, ... 72 —á
RSABE: –Ω–µ –ø—Ä–∏–º–µ–Ω—è–µ—Ç—Å—è (CV < 30%)
```

### –†–µ–∑—É–ª—å—Ç–∞—Ç
```
–ò–¥–µ–Ω—Ç–∏—Ñ–∏–∫–∞—Ç–æ—Ä: –∞–º–ª–æ–¥–∏–ø–∏–Ω-BE
–ù–∞–∑–≤–∞–Ω–∏–µ: –û—Ç–∫—Ä—ã—Ç–æ–µ —Ä–∞–Ω–¥–æ–º–∏–∑–∏—Ä–æ–≤–∞–Ω–Ω–æ–µ –¥–≤—É—Ö–ø–µ—Ä–∏–æ–¥–Ω–æ–µ –ø–µ—Ä–µ–∫—Ä—ë—Å—Ç–Ω–æ–µ –∏—Å—Å–ª–µ–¥–æ–≤–∞–Ω–∏–µ
  —Å—Ä–∞–≤–Ω–∏—Ç–µ–ª—å–Ω–æ–π —Ñ–∞—Ä–º–∞–∫–æ–∫–∏–Ω–µ—Ç–∏–∫–∏ (–±–∏–æ—ç–∫–≤–∏–≤–∞–ª–µ–Ω—Ç–Ω–æ—Å—Ç–∏) –ø—Ä–µ–ø–∞—Ä–∞—Ç–æ–≤
  –ê–º–ª–æ–¥–∏–ø–∏–Ω-–¢–µ—Å—Ç, —Ç–∞–±–ª–µ—Ç–∫–∏, 10 –º–≥ (–û–û–û "–§–∞—Ä–º–∞–¢–µ—Å—Ç", –†–æ—Å—Å–∏—è)
  –∏ —Ä–µ—Ñ–µ—Ä–µ–Ω—Ç–Ω–æ–≥–æ –ø—Ä–µ–ø–∞—Ä–∞—Ç–∞ –ù–æ—Ä–≤–∞—Å–∫¬Æ (Viatris Specialty LLC)
  –Ω–∞—Ç–æ—â–∞–∫ —É –∑–¥–æ—Ä–æ–≤—ã—Ö –¥–æ–±—Ä–æ–≤–æ–ª—å—Ü–µ–≤.
–í–µ—Ä—Å–∏—è: 1.0 –æ—Ç 25 —Ñ–µ–≤—Ä–∞–ª—è 2026 –≥–æ–¥–∞
```

---

## –ü—Ä–∏–º–µ—Ä: –í—ã—Å–æ–∫–æ–≤–∞—Ä–∏–∞–±–µ–ª—å–Ω—ã–π –ø—Ä–µ–ø–∞—Ä–∞—Ç (CVintra = 45%, RSABE)

### –û—Ç–ª–∏—á–∏—è –æ—Ç —Å—Ç–∞–Ω–¥–∞—Ä—Ç–Ω–æ–≥–æ
```
–î–∏–∑–∞–π–Ω: replicated (4-period, TRTR/RTRT)
RSABE –¥–ª—è Cmax:
  swR = ‚àöln(1 + 0.45¬≤) = 0.4294
  –ì—Ä–∞–Ω–∏—Ü—ã: exp(¬±0.76 √ó 0.4294) = [72.15%; 138.59%]
AUC: —Å—Ç–∞–Ω–¥–∞—Ä—Ç–Ω—ã–µ 80‚Äì125%
```

---

## –§–∞–π–ª—ã

| –§–∞–π–ª | –û–ø–∏—Å–∞–Ω–∏–µ |
|---|---|
| `pipeline/stage3.py` | –û—Å–Ω–æ–≤–Ω–∞—è –ª–æ–≥–∏–∫–∞ Stage 3 |
| `pipeline/sample_size.py` | –†–∞—Å—á—ë—Ç –≤—ã–±–æ—Ä–∫–∏ (PowerTOST) |
| `pipeline/timepoints.py` | –ì–µ–Ω–µ—Ä–∞—Ü–∏—è –≥—Ä–∞—Ñ–∏–∫–∞ –∫—Ä–æ–≤–∏ |
| `pipeline/models.py` | DrugInfo, PKParams |
| `pipeline/stage2.py` | Stage2Result |
| `docs/rule85_context.md` | –í—ã–∂–∏–º–∫–∞ –∏–∑ –ü—Ä–∞–≤–∏–ª–∞ 85 |
| `docs/instructions.docx` | –®–∞–±–ª–æ–Ω—ã –∏ –∏–Ω—Å—Ç—Ä—É–∫—Ü–∏–∏ –¥–ª—è –∫–∞–∂–¥–æ–≥–æ –ø–æ–ª—è |
| `1_üíä_–ê–Ω–∞–ª–∏–∑.py` | Streamlit UI (–≤—Å–µ 3 —Å—Ç–∞–¥–∏–∏) |
